# A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

> **NCT06075095** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 297 (actual)

## Conditions studied

- COPD (Chronic Obstructive Pulmonary Disease)

## Interventions

- **DRUG:** BGF MDI HFO 320/14.4/9.6μg
- **DRUG:** BGF MDI HFA 320/14.4/9.6 μg
- **DRUG:** Placebo MDI HFA

## Key facts

- **NCT ID:** NCT06075095
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-11
- **Primary completion:** 2025-08-12
- **Final completion:** 2025-08-12
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075095, "A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06075095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*